Navigation Links
MIODx Licenses Key Immunotherapy Technologies from UCSF
Date:2/23/2017

SAN JOSE, Calif., Feb. 23, 2017 /PRNewswire/ -- MIODx announced today that it has signed an exclusive license for two key immunotherapy technologies from the University of California, San Francisco (UCSF).  The first technology provides a method to monitor a patient for response to immune checkpoint inhibitor therapy such as PD-L1 and CTLA-4.  The second license extends the technology with a method to detect if a patient is likely to have an immune-related adverse event (IRAE) from their immunotherapy regimen.

"Diagnostic assays that help guide immunotherapies represent a huge unmet clinical need," said Lawrence Fong, MD, a science advisor to MIODx and leader of the Cancer Immunotherapy Program at the Helen Diller Family Comprehensive Cancer Center at UCSF. "Rather than treating all patients, we need to select patients who can respond to these treatments as well as determine which patients may develop side effects." 

Immunotherapies have shown tremendous gains in the treatment of certain cancers.  The field of cancer immunotherapies has exploded with hundreds of drugs currently in clinical trials or in development. 

"While we are very excited by what we see in terms of the effect these drugs have on certain patient populations, we believe that there remains a critical need to monitor patients, as there is still a huge unknown on what is happening to their immune system," said MIODx CEO M. Allen Northrup, PhD, FRSC.

This partnership was facilitated by the UCSF Office of Technology Management (OTM), which coordinates UCSF's efforts in forging collaborations and licensing technologies that translate cutting-edge science on campus into products and therapies that directly benefit people worldwide.

MIODx also announced that they have entered into an agreement with UCSF to provide immunosequencing services as part of the validation and commercialization of the technology. 

"We plan on having two paths forward for the immunosequencing platform," said Sean Givens, the company's COO.   "As a research service for pharma and academics working on checkpoint inhibitor therapies, and as a doctor-ordered test for oncologists to monitor their patients that are undergoing immunotherapy."

MIODx has already begun working with collaborators and expects to launch the research service in Q2 2017.

About MIODx

MIODx is a privately held company leading the discovery of early detection and prognostic cancer biomarkers through the company's proprietary platforms. The company's VerifyDx™ platform utilizes a highly sensitive, multiplex PCR assay and advanced bioinformatics to interrogate multiple DNA and RNA pathways that are implicated in highly metastatic cancer. In addition to the VerifyDx™ platform, MIODx utilizes high throughput immune sequencing to generate information on T and B cell diversity that is being applied to monitoring a patient's response to immunotherapy.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/miodx-licenses-key-immunotherapy-technologies-from-ucsf-300412111.html


'/>"/>
SOURCE MIODx
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Jill Hagenkord MD Joins MIODx Board of Directors
2. Teewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard
3. PogoTec™ Licenses WiTricity® Technology to Enable Wireless Energy Transfer for Electronic Devices Associated with Eyewear
4. Brain Sentry Licenses Breakthrough Wearable Sensor Technology from Johns Hopkins University
5. Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up
6. Neogen licenses Cargill patents
7. FDA, EMA Extend Licenses for Aptiv Solutions ADDPLAN® Software for Clinical Trials
8. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
9. Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
10. Genomatica Licenses TeselaGen Software for DNA Design
11. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical ... data and document anonymization solution on October 4, 2017. Shadow is ... field to comply with policy 0070 of the European Medicines Agency ... data. ... GCE Solutions ...
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:6/30/2017)... 2017 Today, American Trucking Associations announced ... face and eye tracking software, became the newest ... "Artificial intelligence and advanced sensing ... a driver,s attentiveness levels while on the road.  ... detect fatigue and prevent potential accidents, which could ...
Breaking Biology News(10 mins):